12:00 AM
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PA32540: Additional Phase I data

Additional data from the open-label, crossover Phase I Co-Rx trial in 30 healthy volunteers showed that PA32540 plus Plavix clopidogrel led to significantly greater inhibition of adenosine diphosphate (ADP)-induced platelet aggregation vs. standard of care (46.5% vs. 39.9%, respectively; p=0.004). Subjects received PA32540 in the morning plus 300 mg Plavix over 10 hours later on day 1, followed by PA32540 in the morning...

Read the full 304 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >